Clinical trials: Hepatitis D, Chronic
Chronic Hepatitis b
A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults
The purpose of this first time in humans trial is to evaluate the safety, reactogenicity and immunogenicity of repeated administrations of AVX70371 in healthy participants.
- Trial name
- RUBY (NCT06989788)
- Testing
- AVX70371
- Where
- Belgium
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstriVax Therapeutics
Chronic Hepatitis D Infection
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
This is a Phase 3, global, randomized, open-label, multicenter, trial evaluating brelovitug (BJT-778) vs bulevirtide for the treatment of chronic hepatitis delta infection (CHD).
- Trial name
- NCT07200908
- Testing
- Brelovitug 300 mg, Bulevirtide 2 mg and Brelovitug - 300 mg
- Where
- 57 sites in Austria, Czechia and 10 more
- Volunteers
- 172 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Chronic Hepatitis B, Alcoholic Hepatitis
Alcohol Consumption and Plasma cfDNA Methylation in Chronic Hepatitis B
This is an observational, exploratory study designed to investigate the effect of different levels of alcohol consumption on plasma cell-free DNA (cfDNA) methylation profiles in participants with chronic hepatitis B.
- Trial name
- NCT07865520
- Testing
- Alcohol Consumption
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Hepatitis C
A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients
Hepatitis C infection is a major public health problem with nearly 175 million infected individuals worldwide. Although cure is possible, only 20-40% of patients spontaneously resolve infection and 40-80% of chronically infected…
- Trial name
- NCT01567540
- Testing
- Sitagliptin
- Where
- 4 sites in France
- Volunteers
- 3 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Chronic Hepatitis b
Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)
This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B…
- Trial name
- Neptune (NCT04202653)
- Testing
- ETV, TQ-A3334, TQ-B2450
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tongji Hospital
Chronic Hepatitis B
VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B
Background: Chronic hepatitis B virus (HBV) infection affects 292 million people worldwide; 887,000 die each year from cirrhosis, liver cancer, and related issues. Treatment options are limited.
- Trial name
- NCT06092333
- Testing
- VIR-2218 and peginterferon alfa-2a
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis Delta With Hepatitis B Carrier State, Chronic Hepatitis b
Hepatitis Delta Virus Infection: Cross-sectional Study in Patients With Chronic Hepatitis B Virus Infection
The goal of this observational study is to determine the prevalence of hepatitis D virus (HDV) and the distribution of the HDV genotype in patients with chronic hepatitis B infection.
- Trial name
- NCT06638320
- Where
- 3 sites in Vietnam
- Volunteers
- 2,452 people
- Sponsor
- Tam Anh Research Institute
Chronic Hepatitis B
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
This is a multicenter, randomized, double-blind, placebo-controlled Phase III study with an open-label extension. The purpose is to evaluate efficacy and safety in adult patients with chronic hepatitis B virus infection who have…
- Trial name
- NCT07797231
- Testing
- TQA3605 tablets, Entecavir dispersible tablets, Tenofovir Disoproxil Fumarate Tablets
- Where
- 77 sites in China
- Volunteers
- 930 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hepatitis B
Impact of Functional Cure of Chronic Hepatitis B on Patient-Reported Outcomes (PROs)
This single-center comparative cross-sectional study includes a prospective longitudinal follow-up cohort. At least 400 subjects from the "Everest Project" cohort will be enrolled into four groups: clinical-cure, non-cure…
- Trial name
- NCT07855029
- Testing
- Observation-based data collection via patient-reported questionnaires
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Zhiliang Gao
HDV, HDV Infection
D-SOLVE Cohorts (Cohort A and B)
Hepatitis D is by far the most severe form of chronic viral hepatitis, frequently leading to liver failure, hepatocellular carcinoma and death.
- Conditions
- HDV, HDV Infection, Chronic Liver Disease
- Trial name
- HDV750 (NCT06160635)
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 750 people
- Sponsor
- Hannover Medical School
Chronic Hepatitis B
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (A)
Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of…
- Trial name
- NCT07852091
- Testing
- Sintilimab/Envafolimab, ETV/TDF/TAF
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Chronic Hepatitis B Virus Infection
A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B
This study will examine the safety and tolerability of single and multiple doses of IB-001 in two parts: Part A: SAD study in approximately 50 Healthy Volunteers (HV).
- Trial name
- NCT07389044
- Testing
- IB-001, Peginterferon Alfa-2A
- Where
- 5 sites in Hong Kong, Moldova and 2 more
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- IntegerBio
Chronic Hepatitis B, Anti-PD-1 Antibody
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)
Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of…
- Conditions
- Chronic Hepatitis B, Anti-PD-1 Antibody, Anti-PD-L1 Antibody, Peg-IFNα
- Trial name
- NCT07845058
- Testing
- anti-PD-1/anti-PD-L1 antibody, NAs, PEG-IFNα
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Chronic Hepatitis D Infection
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
- Trial name
- LOWR-1 (NCT02430181)
- Testing
- lonafarnib, peginterferon alfa-2a, ritonavir
- Where
- Turkey (Türkiye)
- Volunteers
- 21 people
- Sponsor
- EIT Pharma, Inc.
Chronic Hepatitis D Infection
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).
- Trial name
- LOWR-2 (NCT02430194)
- Testing
- lonafarnib, ritonavir, Pegylated interferon-alfa-2a
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people
- Sponsor
- EIT Pharma, Inc.
Chronic Delta Hepatitis
Titrating-Dose of Lonafarnib in Combination With Ritonavir
A phase 2, open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic activity of titrating-dose lonafarnib/ritonavir in patients chronically infected with hepatitis delta virus (HDV)
- Trial name
- LOWR-4 (NCT02527707)
- Testing
- lonafarnib, Ritonavir
- Volunteers
- 15 people
- Sponsor
- EIT Pharma, Inc.
Hepatitis B, Chronic
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).
- Trial name
- ASPIRE-202 (NCT07654283)
- Testing
- AHB-137
- Where
- 10 sites in United States, Canada and 4 more
- Volunteers
- 70 people
- Sponsor
- AusperBio Therapeutics Inc.
Thrombocytopenia Related to Chronic Liver Disease
Effect of Rifaximin on Thrombocytopenia in Patients With HCV-Related Liver Cirrhosis
Cirrhosis is a common complication of chronic hepatitis C virus (HCV) infection in Egypt. Thrombocytopenia (TP) is the most common cytopenia in patients with cirrhosis and may be associated with variceal bleeding, rebleeding…
- Trial name
- NCT07791940
- Testing
- Rifaximin (drug)
- Where
- 2 sites in Egypt
- Volunteers
- 200 people
- Sponsor
- Fayoum University Hospital
Chronic Hepatitis b, Anti-PD-1 Antibody
A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)
Hepatitis B virus (HBV) infection is a major public health threat in China. At present, a functional cure, also known as clinical cure or sustained Hepatitis B surface antigen (HBsAg) loss, is recommended as the ideal endpoint of…
- Trial name
- NCT05769816
- Testing
- Anti-PD-1 antibody, NAs
- Where
- China
- Volunteers
- 120 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Chronic Liver Disease
Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases
The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of mobile chat messaging for reducing alcohol use among patients with chronic liver diseases.
- Trial name
- NCT06587568
- Testing
- Mobile chat messaging, Screening, brief intervention and referral to treatment
- Where
- Hong Kong
- Volunteers
- 106 people
- Sponsor
- The University of Hong Kong